Submitted:
19 September 2024
Posted:
19 September 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Material and Method
2.1. Ethical Approval
2.2. Research Design
2.3. Inclusion Criteria
2.4. Exlusion Criteria
2.5. Sample collection and measurements
2.6. Measurement of serum otoconin 90 (OC90) levels
2.7. Measurement of serum otolin-1 levels
2.8. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Strupp, M., Mandalà, M., López-Escámez, J. A. Peripheral vestibular disorders. Current Opinion in Neurology 2019, 32, 165–173. [CrossRef]
- Yang TH, Xirasagar S, Cheng YF, Chen CS, Lin HC. Increased prevalence of peripheral vestibular disorder among patients with Fabry disease. Orphanet J Rare Dis. 2024;19:97. [CrossRef]
- Welgampola MS, Akdal G, Halmagyi GM. Neuro-otology- some recent clinical advances [published correction appears in J Neurol. 2017 Jan;264(1):204. doi: 10.1007/s00415-016-8320-z]. J Neurol. 2017;264:188-203. [CrossRef]
- Maudoux A, Vitry S, El-Amraoui A. Vestibular Deficits in Deafness: Clinical Presentation, Animal Modeling, and Treatment Solutions. Front Neurol. 2022;13:816534. [CrossRef]
- Gomaa NA, Jimoh Z, Campbell S, Zenke JK, Szczepek AJ. Biomarkers for Inner Ear Disorders: Scoping Review on the Role of Biomarkers in Hearing and Balance Disorders. Diagnostics (Basel). 2020;11:42. [CrossRef]
- Deans MR, Peterson JM, Wong GW. Mammalian Otolin: a multimeric glycoprotein specific to the inner ear that interacts with otoconial matrix protein Otoconin-90 and Cerebellin-1. PLoS One. 2010;5:e12765. [CrossRef]
- Yang H, Zhao X, Xu Y, Wang L, He Q, Lundberg YW. Matrix recruitment and calcium sequestration for spatial specific otoconia development. PLoS One. 2011;6(5):e20498. [CrossRef]
- Andrade LR, Lins U, Farina M, Kachar B, Thalmann R. Immunogold TEM of otoconin 90 and otolin - relevance to mineralization of otoconia, and pathogenesis of benign positional vertigo. Hear Res. 2012;292(1-2):14-25. [CrossRef]
- Fan Z, Hu Z, Han W, et al. High Serum Levels of Otolin-1 in Patients With Benign Paroxysmal Positional Vertigo Predict Recurrence. Front Neurol. 2022;13:841677. [CrossRef]
- Zhao X, Yang H, Yamoah EN, Lundberg YW. Gene targeting reveals the role of Oc90 as the essential organizer of the otoconial organic matrix. Dev Biol. 2007;304(2):508-524. [CrossRef]
- Huang S, Qian S. Advances in otolith-related protein research. Front Neurosci. 2022; 16:956200. [CrossRef]
- Epley JM. Human experience with canalith repositioning maneuvers. Ann N Y Acad Sci 2001; 942: 179–191. [CrossRef]
- Nuti D, Zee DS, Mandalà M. Benign Paroxysmal Positional Vertigo: What We Do and Do Not Know. Semin Neurol. 2020;40(1):49-58. [CrossRef]
- Guerra J, Devesa J. Causes and treatment of idiopathic benign paroxysmal positional vertigo based on endocrinological and other metabolic factors. J Otol. 2020;15(4):155-160. [CrossRef]
- Lundberg YW, Xu Y, Thiessen KD, Kramer KL. Mechanisms of otoconia and otolith development. Dev Dyn. 2015;244(3):239-253. [CrossRef]
- Bi J, Liu B, Zhang Y, Zhou Q. Study on the Bone Metabolism Indices and Otoconin-90 in Benign Paroxysmal Positional Vertigo. Otol Neurotol. 2021;42(6):e744-e749. [CrossRef]
- Zhang S, Xing J, Gong Y, Li P, Wang B, Xu L. Downregulation of VDR in benign paroxysmal positional vertigo patients inhibits otolith-associated protein expression levels. Mol Med Rep. 2021;24(2):591. [CrossRef]
- Parham K, Sacks D, Bixby C, Fall P. Inner ear protein as a biomarker in circulation?. Otolaryngol Head Neck Surg. 2014;151(6):1038-1040. [CrossRef]
- Tabtabai R, Haynes L, Kuchel GA, Parham K. Age-Related Increase in Blood Levels of Otolin-1 in Humans. Otol Neurotol. 2017;38(6):865-869. [CrossRef]
- Feng MY, Zhuang JH, Gu HH, Tian Q, Zhang ZH. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019;33(12):1138-1147.
- Sacks D, Parham K. Preliminary Report on the Investigation of the Association Between BPPV and Osteoporosis Using Biomarkers. Otol Neurotol. 2015;36(9):1532-1536. [CrossRef]
- Parham K, Kuchel GA. A Geriatric Perspective on Benign Paroxysmal Positional Vertigo. J Am Geriatr Soc. 2016;64(2):378-385. [CrossRef]
- Qian S, Zhang X, Wang Y. Serum Estradiol Correlates With Benign Paroxysmal Positional Vertigo in Postmenopausal Women. Endocr Pract. 2022;28(7):673-677. [CrossRef]
- Wu Y, Han W, Yan W, Lu X, Zhou M, Li L, Guan Q, Fan Z. Increased Otolin-1 in Serum as a Potential Biomarker for Idiopathic Benign Paroxysmal Positional Vertigo Episodes. Front Neurol. 2020;11:367. [CrossRef]
- McKenna K, Rahman K, Parham K. Otoconia degeneration as a consequence of primary hyperparathyroidism. Med Hypotheses. 2020;144:109982. [CrossRef]
- Irugu DVK, Singh A, Yadav H, et al. Serum otolin-1 as a biomarker for benign paroxysmal positional vertigo: a case-control study. J Laryngol Otol. 2021;135(7):589-592. [CrossRef]
- Liu X, Han K, Zhou M, Wu Y. Association between otolin-1 and benign paroxysmal positional vertigo: A meta-analysis. Front Neurol. 2022;13:950023. [CrossRef]
- Singh A, Yadav H, Verma H, Sikka K, Abraham RA, Irugu DVK. Normal Serum Levels of Otolin-1 in Patients with Meniere Disease in Remission. Int Arch Otorhinolaryngol. 2023;27(3):e440-e444. [CrossRef]
- Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiological reviews 2005;85:373-422. [CrossRef]
- Yamauchi D, Raveendran NN, Pondugula SR, Kampalli SB, Sanneman JD, Harbidge DG, Marcus DC. Vitamin D upregulates expression of ECaC1 mRNA in semicircular canal. Biochem Biophys Res Commun 2005; 331:1353-1357. [CrossRef]
- Jeong SH, Kim JS, Shin JW, et al. Decreased serum vitamin D in idiopathic benign paroxysmal positional vertigo. J Neurol. 2013;260(3):832-838. [CrossRef]
- Büki B, Ecker M, Jünger H, Lundberg YW. Vitamin D deficiency and benign paroxysmal positioning vertigo. Med Hypotheses. 2013;80(2):201-204. [CrossRef]
- Talaat HS, Abuhadied G, Talaat AS, Abdelaal MS. Low bone mineral density and vitamin D deficiency in patients with benign positional paroxysmal vertigo. Eur Arch Otorhinolaryngol. 2015;272(9):2249-2253. [CrossRef]
- Sheikhzadeh M, Lotfi Y, Mousavi A, Heidari B, Bakhshi E. The effect of serum vitamin D normalization in preventing recurrences of benign paroxysmal positional vertigo: A case-control study. Caspian J Intern Med. 2016;7(3):173-177.
- Rhim GI. Serum vitamin D and recurrent benign paroxysmal positional vertigo. Laryngoscope Investig Otolaryngol. 2016;1(6):150-153. [CrossRef]
- Karataş A, Acar Yüceant G, Yüce T, Hacı C, Cebi IT, Salviz M. Association of Benign Paroxysmal Positional Vertigo with Osteoporosis and Vitamin D Deficiency: A Case Controlled Study. J Int Adv Otol. 2017;13(2):259-265. [CrossRef]
- Ren YY, Wang YJ, Li JL, Liu M, Xia F. Low vitamin D and uric acid status in patients with benign paroxysmal positional vertigo. Sci Prog. 2023;106(4):368504231205397. [CrossRef]
- Rhim G, Kim MJ. Vitamin D Supplementation and Recurrence of Benign Paroxysmal Positional Vertigo. Nutrients. 2024;16(5):689. [CrossRef]
- Jeong SH, Kim JS, Kim HJ, et al. Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial. Neurology. 2020;95(9):e1117-e1125. [CrossRef]
- Abdelmaksoud AA, Fahim DFM, Bazeed SES, Alemam MF, Aref ZF. Relation between vitamin D deficiency and benign paroxysmal positional vertigo. Sci Rep. 2021;11(1):16855. [CrossRef]
- Sharma K, Ojha T, Dabaria R, Chhabra B, Trivedi BB, Bansal M. Relation Between Posterior Canal Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 3):4405-4408. [CrossRef]


| Case | Control | ||||
|---|---|---|---|---|---|
| n | % | n | % | P value | |
| Gender | |||||
| Male | 24 | 45.83% | 13 | 34.62% | 0.350* |
| Female | 26 | 54.17% | 17 | 65.38% | |
| Age (mean±std) | 42.46±11.4 | 38.69±11.2 | 0.176† | ||
| Tinnitus | 14 | 29.17% | |||
| Right | 5 | 35.71% | - | - | - |
| Left | 9 | 64.29% | - | - | |
| Duration | |||||
| <1 week | 14 | 29.17% | - | - | - |
| 1-3 week | 26 | 54.17% | - | - | |
| ≥4 week | 8 | 16.67% | - | - | |
| Cause | |||||
| Idiopathic | 26 | 52% | - | - | - |
| After the URI | 20 | 40% | - | - | |
| Traumatic | 2 | 4% | - | - | |
| Pressure difference | 2 | 4% | - | - | |
| Neurological examination | |||||
| Normal | 30 | 60.00% | - | - | - |
| Nystagmus | 20 | 40.00% | - | - | |
| Case | Control | ||
|---|---|---|---|
| mean±std or median (25p-75p) | mean±std or median (25p-75p) | p value | |
| Otoconin-90 (ng/L) | 655.13(553.47-1505.27) | 712.75(623.59-832.12) | 0.892¥ |
| Otolin-1 (pg/mL) | 710.44(584.35-837.39) | 280.45(212.7-419.61) | <0.001¥ |
| Calcium (mg/dL) | 8.93±0.57 | 9.18±0.55 | 0.091† |
| Parathormone (pg/mL) | 48.25±19.57 | 38.71±12.32 | 0.051† |
| Vitamin D (ng/mL) | 14.3(8.45-17.5) | 26.25(21-32) | <0.001¥ |
| Immature granulocyte (IG) (%) | 0.2(0.2-0.3) | 0.2(0.2-0.3) | 0.918¥ |
| White blood cell (103/µL) | 7.1(5.8-9.1) | 6.42(5.9-8.17) | 0.389¥ |
| Red blood cell (106/µL) | 4.7(4.5-4.9) | 4.6(4.25-5) | 0.258¥ |
| Hemoglobin (g/dL) | 13.38±1.43 | 13.6±1.49 | 0.539† |
| Hematocrit (%) | 41.5±2.34 | 40.55±3.9 | 0.264† |
| Platelet (106/µL) | 200.5(180-223.5) | 226(210-259) | 0.004¥ |
| Lymphocytes (103/µL) | 2.65(2.25-3.1) | 2.44(2.04-2.6) | 0.107¥ |
| Lymphocytes (%) | 29.7(27.5-34.5) | 32(28-33.6) | 0.662¥ |
| Neutrophil (103/µL) | 3.95(3-5.45) | 2.98(2.57-3.31) | <0.001¥ |
| Neutrophil (%) | 54.01±7.8 | 29.8±3.91 | <0.001† |
| Monocyte (103/µL) | 0.6(0.5-0.72) | 0.5(0.42-0.6) | 0.013¥ |
| Monocyte (%) | 7.2(6.4-8.9) | 7.6(6.8-8.4) | 0.747¥ |
| Eosinophil (103/µL) | 0.21(0.11-0.32) | 0.15(0.1-0.2) | 0.094¥ |
| Eosinophil (%) | 1.8(1.2-3.1) | 2(1.5-2.9) | 0.765¥ |
| CRP (mg/L) | 3.3(2-5.35) | 1.18(0.68-1.7) | <0.001¥ |
| Neutrophil lymphocyte ratio (NLR) | 1.66±0.52 | 1.29±0.37 | 0.001† |
| Platelet lymphocyte ratio (PLR) | 78.04(62-94.74) | 98(85.6-117.96) | 0.003¥ |
| Systemic immune-inflammation index (SII) | 335.6(227.89-425.03) | 314.22(227.5-365.69) | 0.389¥ |
| Case | Control | ||
|---|---|---|---|
| Otolin-1 | mean±std | 685.85±202.72 | 307.88±110.43 |
| Median (25p-75p) | 710.44(584.35-837.39) | 280.45(212.7-419.61) | |
| Median (Min–Max) | 710.44(307.17-997.37) | 280.45(159.31-523.51) | |
| Variables | AUC | 95 CI of AUC | p value | Cutoff | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Otolin-1 | 0.933 | 0.881-0.986 | <0.001 | 525¶ | 79.17% | 100% |
| CRP | 0.867 | 0.787-0.947 | <0.001 | 2¶ | 79.17% | 80.77% |
| 2.2¶ | 68.75% | 96.15% | ||||
| NLR | 0.705 | 0.587-0.823 | 0.004 | 1.65¶ | 50.00% | 84.62% |
| PLR | 0.713 | 0.588-0.838 | 0.003 | 87.5* | 72.92% | 73.08% |
| Vitamin D | 0.913 | 0.848-0.979 | <0.001 | 20* | 83.33% | 88.46% |
| All Group | |||
|---|---|---|---|
| Otoconin-90 (ng/L) | Vitamin D | ||
| Otolin-1 (pg/mL) | r | 0.393 | -0.682 |
| p | 0.001 | <0.001 | |
| Otoconin-90 (ng/L) | r | -0.404 | |
| p | <0.001 | ||
| Cases | |||
| Otoconin-90 (ng/L) | Vitamin D | ||
| Otolin-1 (pg/mL) | r | 0.693 | -0.586 |
| p | <0.001 | <0.001 | |
| Otoconin-90 (ng/L) | r | -0.672 | |
| p | <0.001 | ||
| Control | |||
| Otoconin-90 (ng/L) | Vitamin D | ||
| Otolin-1 (pg/mL) | r | 0.039 | 0.181 |
| p | 0.851 | 0.376 | |
| Otoconin-90 (ng/L) | r | -0.151 | |
| p | 0.460 | ||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).